Low-molecular-weight heparins

Pharmacoeconomic decision modeling based on meta-analysis data

Edmundas Kadusevicius, Gabriele Kildonaviciute, Birute Varanaviciene, Danguole Jankauskiene

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Objectives: The aim of this study was to compare efficacy, safety, and consumption of low-molecular-weight heparins with unfractionated heparin, and to develop a pharmacoeconomic decision model based on meta-analysis data. Methods: Review and meta-analysis were performed of published randomized control trials directly comparing the safety and efficacy of low-molecular-weight heparins (LMWHs)that is, nadroparin, enoxaparin, and dalteparinand unfractionated heparin (UFH) was performed by two reviewers using inclusion/exclusion criteria based on the research objectives. The value of fixed effects and random effects odds ratio (95 percent confidence interval) was calculated for each trial for the composite end point. Subsequently, a pharmacoeconomic decision modeling based on reference pricing methodology was implemented. Results: In comparison to UFH, all LMWHs have independently demonstrated greater safety and effectiveness. None of the LMWHs demonstrated a significant superiority over each other; therefore, the group of LMWHs was interchangeable and suitable for cost minimization analysis and reference price implementation. Being the least expensive option, dalteparin single DDD price was set as the reference. Introduction of reference pricing for LMWHs would decrease the total expenditure on LMWHs of approximately 30 percent and would result in total savings of 1.830-2.070 thousand LTL in the country of Lithuania (approximately 0.8 million USD) per year. Conclusions: The meta-analysis results of LMWHs could be used to support a policy on reference-based pricing and pharmacoeconomic decision modeling in healthcare institutions, which would allow a decrease in healthcare expenditures.

Original languageEnglish
Pages (from-to)272-279
Number of pages8
JournalInternational Journal of Technology Assessment in Health Care
Volume26
Issue number3
DOIs
Publication statusPublished - Jul 2010

Fingerprint

Pharmaceutical Economics
Decision Support Techniques
Low Molecular Weight Heparin
Meta-Analysis
Heparin
Costs and Cost Analysis
Health Expenditures
Safety
Nadroparin
Dalteparin
Lithuania
Delivery of Health Care
Enoxaparin
Dichlorodiphenyldichloroethane
Odds Ratio
Confidence Intervals

Keywords

  • Cost-minimization
  • Low-molecular-weight heparins (LMWHs)
  • Meta-analysis
  • Reference pricing
  • Unfractionated heparin (UFH)

ASJC Scopus subject areas

  • Health Policy

Cite this

Low-molecular-weight heparins : Pharmacoeconomic decision modeling based on meta-analysis data. / Kadusevicius, Edmundas; Kildonaviciute, Gabriele; Varanaviciene, Birute; Jankauskiene, Danguole.

In: International Journal of Technology Assessment in Health Care, Vol. 26, No. 3, 07.2010, p. 272-279.

Research output: Contribution to journalArticle

Kadusevicius, Edmundas ; Kildonaviciute, Gabriele ; Varanaviciene, Birute ; Jankauskiene, Danguole. / Low-molecular-weight heparins : Pharmacoeconomic decision modeling based on meta-analysis data. In: International Journal of Technology Assessment in Health Care. 2010 ; Vol. 26, No. 3. pp. 272-279.
@article{da9364a91f524592bfeba09d60542bc0,
title = "Low-molecular-weight heparins: Pharmacoeconomic decision modeling based on meta-analysis data",
abstract = "Objectives: The aim of this study was to compare efficacy, safety, and consumption of low-molecular-weight heparins with unfractionated heparin, and to develop a pharmacoeconomic decision model based on meta-analysis data. Methods: Review and meta-analysis were performed of published randomized control trials directly comparing the safety and efficacy of low-molecular-weight heparins (LMWHs)that is, nadroparin, enoxaparin, and dalteparinand unfractionated heparin (UFH) was performed by two reviewers using inclusion/exclusion criteria based on the research objectives. The value of fixed effects and random effects odds ratio (95 percent confidence interval) was calculated for each trial for the composite end point. Subsequently, a pharmacoeconomic decision modeling based on reference pricing methodology was implemented. Results: In comparison to UFH, all LMWHs have independently demonstrated greater safety and effectiveness. None of the LMWHs demonstrated a significant superiority over each other; therefore, the group of LMWHs was interchangeable and suitable for cost minimization analysis and reference price implementation. Being the least expensive option, dalteparin single DDD price was set as the reference. Introduction of reference pricing for LMWHs would decrease the total expenditure on LMWHs of approximately 30 percent and would result in total savings of 1.830-2.070 thousand LTL in the country of Lithuania (approximately 0.8 million USD) per year. Conclusions: The meta-analysis results of LMWHs could be used to support a policy on reference-based pricing and pharmacoeconomic decision modeling in healthcare institutions, which would allow a decrease in healthcare expenditures.",
keywords = "Cost-minimization, Low-molecular-weight heparins (LMWHs), Meta-analysis, Reference pricing, Unfractionated heparin (UFH)",
author = "Edmundas Kadusevicius and Gabriele Kildonaviciute and Birute Varanaviciene and Danguole Jankauskiene",
year = "2010",
month = "7",
doi = "10.1017/S0266462310000310",
language = "English",
volume = "26",
pages = "272--279",
journal = "International Journal of Technology Assessment in Health Care",
issn = "0266-4623",
publisher = "Cambridge University Press",
number = "3",

}

TY - JOUR

T1 - Low-molecular-weight heparins

T2 - Pharmacoeconomic decision modeling based on meta-analysis data

AU - Kadusevicius, Edmundas

AU - Kildonaviciute, Gabriele

AU - Varanaviciene, Birute

AU - Jankauskiene, Danguole

PY - 2010/7

Y1 - 2010/7

N2 - Objectives: The aim of this study was to compare efficacy, safety, and consumption of low-molecular-weight heparins with unfractionated heparin, and to develop a pharmacoeconomic decision model based on meta-analysis data. Methods: Review and meta-analysis were performed of published randomized control trials directly comparing the safety and efficacy of low-molecular-weight heparins (LMWHs)that is, nadroparin, enoxaparin, and dalteparinand unfractionated heparin (UFH) was performed by two reviewers using inclusion/exclusion criteria based on the research objectives. The value of fixed effects and random effects odds ratio (95 percent confidence interval) was calculated for each trial for the composite end point. Subsequently, a pharmacoeconomic decision modeling based on reference pricing methodology was implemented. Results: In comparison to UFH, all LMWHs have independently demonstrated greater safety and effectiveness. None of the LMWHs demonstrated a significant superiority over each other; therefore, the group of LMWHs was interchangeable and suitable for cost minimization analysis and reference price implementation. Being the least expensive option, dalteparin single DDD price was set as the reference. Introduction of reference pricing for LMWHs would decrease the total expenditure on LMWHs of approximately 30 percent and would result in total savings of 1.830-2.070 thousand LTL in the country of Lithuania (approximately 0.8 million USD) per year. Conclusions: The meta-analysis results of LMWHs could be used to support a policy on reference-based pricing and pharmacoeconomic decision modeling in healthcare institutions, which would allow a decrease in healthcare expenditures.

AB - Objectives: The aim of this study was to compare efficacy, safety, and consumption of low-molecular-weight heparins with unfractionated heparin, and to develop a pharmacoeconomic decision model based on meta-analysis data. Methods: Review and meta-analysis were performed of published randomized control trials directly comparing the safety and efficacy of low-molecular-weight heparins (LMWHs)that is, nadroparin, enoxaparin, and dalteparinand unfractionated heparin (UFH) was performed by two reviewers using inclusion/exclusion criteria based on the research objectives. The value of fixed effects and random effects odds ratio (95 percent confidence interval) was calculated for each trial for the composite end point. Subsequently, a pharmacoeconomic decision modeling based on reference pricing methodology was implemented. Results: In comparison to UFH, all LMWHs have independently demonstrated greater safety and effectiveness. None of the LMWHs demonstrated a significant superiority over each other; therefore, the group of LMWHs was interchangeable and suitable for cost minimization analysis and reference price implementation. Being the least expensive option, dalteparin single DDD price was set as the reference. Introduction of reference pricing for LMWHs would decrease the total expenditure on LMWHs of approximately 30 percent and would result in total savings of 1.830-2.070 thousand LTL in the country of Lithuania (approximately 0.8 million USD) per year. Conclusions: The meta-analysis results of LMWHs could be used to support a policy on reference-based pricing and pharmacoeconomic decision modeling in healthcare institutions, which would allow a decrease in healthcare expenditures.

KW - Cost-minimization

KW - Low-molecular-weight heparins (LMWHs)

KW - Meta-analysis

KW - Reference pricing

KW - Unfractionated heparin (UFH)

UR - http://www.scopus.com/inward/record.url?scp=78049434942&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78049434942&partnerID=8YFLogxK

U2 - 10.1017/S0266462310000310

DO - 10.1017/S0266462310000310

M3 - Article

VL - 26

SP - 272

EP - 279

JO - International Journal of Technology Assessment in Health Care

JF - International Journal of Technology Assessment in Health Care

SN - 0266-4623

IS - 3

ER -